

Coronavirus Disease 2019 (COVID-19) Situation Report

Data as reported by national authorities by 24:00 local time 12 April 2021

Situation Report No. 251 - Kingdom of Bahrain

13th of April, 2021





	Global		Eastern Mediterranean Region	
	COVID-19 Cases	COVID-19 Deaths	COVID-19 Cases	COVID-19 Deaths
Total	135,646,617	2,930,732	8,112,093	165,757
New	1,328,633 in 2 days	22,673 in 2 days	102,983 in 2 days	1,359 in 2 days

Kingdom of Bahrain

	Confirmed Cases	Recovered Cases	Deaths	Active Cases	Critical Cases	PCR Tests	Vaccine First Dose	Vaccine Second Dose
Total	157,729	145,953	562	11,214	89	3,798,472	568,892	405,090
New	2,327 in 2 days	2,064 in 2 days	8 in 2 days	-	-	36,941 in 2 days	-	-


HIGHLIGHTS

- The Mortality were: 6 Bahraini citizens (4 Female (35,42,61 and 67 years old) and 2 male (67 and 106 years old)) and 2 male expatriates (57 and 74 years old).
- Increasing number of citizens and residents continue to take COVID-19 Vaccine in Bahrain; and Ministry of Health (MOH) revealed the total number of individuals vaccinated as of 10 April 2021 for the first dose (568,892) and for the second dose (405,090).
- MOH announced that prayers at mosques during the Holy Month of Ramadan will be strictly restricted to those who have recovered from Covid-19 or are 14 days past their second dose of valid vaccination.
- MOH: Citizens and residents have been urged to pick any available Covid-19 vaccine – and not wait for specific ones – as delays may put lives at risk.
- National Medical Taskforce for Combating the Coronavirus announced new/additional public health implementation measures commencing the first day of the Eid al-Fitr holiday.
- Ministries, governmental authorities and public institutions will be working from 8 am to 2 pm during the holy month of Ramadan.
- Registration for an appointment to receive the COVID-19 vaccination is done via either: The Behave Application or by calling 444
- A one-year-old baby girl infected 14 of her immediate family members with coronavirus last week.
- WHO: New research helps to increase understanding of the impact of COVID19 for pregnant women and their babies; see link below.
- WHO: Guidance on informing vaccination programs: a guide to the design and conduct of dengue sero-surveys; see link below.
- WHO: Responding to non-communicable diseases during and beyond the COVID-19 pandemic; see link below.
- WHO: Emergency Global Supply Chain System(COVID-19) catalogue; see link below.
- WHO: Interim guidance on Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapidimmuno assay; see link below.
- WHO: Global TB progress a trisk; see link below.
- WHO: SAGE values framework for the allocation and prioritization of COVID-19 vaccination; see link below.
- WHO: Interim guidance Operational considerations for COVID19 surveillance using GISRS; see link below.
- WHO: Statement by WHO Director of Programme Management on COVID-19 pandemic; see link below.
- WHO: As COVID19 spread accelerates, JHRC Emergency Committee urges focus on measures that work; see link below.
- WHO: ICMAH joint statement on the need for improved global regulatory alignment on COVID-19 medicines and vaccines; see link below.
- WHO Living Guideline: The rapetucids and COVID-19; see link below.
- WHO: Interim guidance on Diagnostics, therapeutics, vaccine readiness, and other health products for COVID-19; see link below.
- WHO: Evidence to recommendations: COVID-19 mitigation in the aviation sector; see link below.
- WHO: Health workforce policy and management in the context of the COVID-19 pandemic response; see link below.
- WHO: COVID-19 vaccine introduction and deployment costing tool; see link below.
- WHO: Considerations for implementing a risk-based approach to international travel in the context of COVID-19; see link below.
- WHO: Risk assessment tool to inform mitigation measures for international travel in the context of COVID-19; see link below.
- WHO: Rational use of personal protective equipment for coronavirus disease (COVID-19) and considerations during severe shortages; see link below.
- WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access; see link below.
- WHO: COVID-19 Virtual Press conference transcript; see link below.
- WHO: Access to COVID-19 tools funding commitment tracker; see link below.
- WHO: New research highlights risks of separating newborns from mothers during COVID-19 pandemic; see link below.
- WHO Guideline Development Group Living Guidelines for COVID-19; see link below.
- WHO statement on AstraZeneca COVID-19 vaccine safety signals; see link below.
- WHO: What is the Access to COVID-19 Tools (ACT) Accelerator, how is it structured and how does it work?; see link below.
- Update 55 – WHO COVID-19 guidelines development process; see link below.
- WHO: Draft landscape and tracker of COVID-19 candidate vaccines; see link below.
- WHO: Interim statement of the COVID-19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety on AstraZeneca COVID-19 vaccine; see link below.
- WHO: COVIDX reaches over 100 economies, 42 days after first international delivery; see link below.



IMPORTANT LINKS

- Daily COVID-19 updates on MOH website: <https://www.moh.gov.bh/>
- WHO's COVID-19 weekly situation reports: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/20200817-weekly-epi-update-1.pdf?fbclid=IwAR1v6449z76_4
- WHO's COVID-19 Dashboard: <https://covid19.who.int/>
- WHO: New research helps to increase understanding of the impact of COVID19 for pregnant women and their babies: <https://www.who.int/news-room/detail/15-04-2021-new-research-helps-to-increase-understanding-of-the-impact-of-covid-19-for-pregnant-women-and-their-babies>
- WHO: Guidance on informing vaccination programs: a guide to the design and conduct of dengue sero-surveys: <https://www.who.int/publications/m/item/978-92-4-123238-9>
- WHO: Responding to non-communicable diseases during and beyond the COVID-19 pandemic: <https://bit.ly/25vtdr>
- WHO: Emergency Global Supply Chain System(COVID-19) catalogue: <https://www.who.int/publications/m/item/emergency-global-supply-chain-system-covid-19-catalogue>
- WHO: Interim guidance on Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapidimmuno assays: <https://doi.org/10.2471/BLT.2020102>
- WHO: SAGE values framework for the allocation and prioritization of COVID-19 vaccination: <https://bit.ly/34APNGG>
- WHO: Interim guidance Operational considerations for COVID19 surveillance using GISRS: <https://bit.ly/34APNGG>
- WHO: Statement by WHO Director of Programme Management on COVID-19 pandemic: <https://bit.ly/1E0F0F>
- WHO: As COVID19 spread accelerates, JHRC Emergency Committee urges focus on measures that work: <https://bit.ly/373066>
- WHO: The path for COVID-19 vaccine: <https://bit.ly/3n5h3a>
- WHO: ICMAH joint statement on the need for improved global regulatory alignment on COVID-19 medicines and vaccines: <https://bit.ly/3a9n5M>
- WHO Living Guideline: The rapetucids and COVID-19: <https://www.who.int/publications/m/item/therapeutics-and-covid-19-living-guideline>
- WHO: Interim guidance on Diagnostics, therapeutics, vaccine readiness, and other health products for COVID-19: https://www.who.int/publications/m/item/WHO-2019-nCoV-HCF_assessment-Products-2020.1
- WHO: Evidence to recommendations: COVID-19 mitigation in the aviation sector: <https://www.who.int/publications/m/item/evidence-to-recommendations-covid-19-mitigation-in-the-aviation-sector>
- WHO: Health workforce policy and management in the context of the COVID-19 pandemic response: <https://www.who.int/publications/m/item/health-workforce-2020-1-eng.pdf>
- COVID-19 vaccine introduction and deployment costing tool: <https://www.who.int/publications/m/item/1566533753>
- WHO: Considerations for implementing a risk-based approach to international travel in the context of COVID-19: <https://www.who.int/publications/m/item/WHO-2019-nCoV-Risk-based-international-travel-2020.1>
- WHO: Risk assessment tool to inform mitigation measures for international travel in the context of COVID-19: https://www.who.int/publications/m/item/WHO-2019-nCoV-Risk-based-international-travel-Assessment_Tool-2020.1
- WHO: Rational use of personal protective equipment for coronavirus disease (COVID-19) and considerations during severe shortages: <https://www.who.int/publications/m/item/rational-use-of-personal-protective-equipment-for-coronavirus-disease-covid-19-and-considerations-during-severe-shortages>
- WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access: <https://www.who.int/news/item/11-04-2021-who-issues-its-first-emergency-use-validation-for-a-covid-19-vaccine-and-emphasizes-need-for-equitable-global-access>
- WHO: COVID-19 Virtual Press conference transcript: <https://www.who.int/publications/m/item/covid-19-virtual-press-conference-transcript-8-march-2021>
- WHO: Access to COVID-19 tools funding commitment tracker: <https://www.who.int/publications/m/item/access-to-covid-19-tools-funding>
- WHO: New research highlights risks of separating newborns from mothers during COVID-19 pandemic: <https://www.who.int/news/item/15-04-2021-new-research-highlights-risks-of-separating-newborns-from-mothers-during-covid-19-pandemic>
- WHO Guideline Development Group Living Guidelines for COVID-19: <https://www.who.int/publications/m/item/who-guideline-development-group-living-guidelines-for-covid-19-biographies>
- WHO statement on AstraZeneca COVID-19 vaccine safety signals: <https://www.who.int/news/item/07-04-2021-statement-on-astrazeneca-covid-19-vaccine-safety-signal>
- WHO: What is the Access to COVID-19 Tools (ACT) Accelerator, how is it structured and how does it work? <https://www.who.int/publications/m/item/what-is-the-access-to-covid-19-tools-act-accelerator-how-is-it-structured-and-how-does-it-work>
- Update 55 – WHO COVID-19 guidelines development process: <https://www.who.int/publications/m/item/update-55-who-covid-19-guidelines-development-process>
- WHO: Draft landscape and tracker of COVID-19 candidate vaccines: <https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines>
- WHO: Interim statement of the WHO Global Advisory Committee on Vaccine Safety on AstraZeneca COVID-19 vaccine: <https://www.who.int/news/item/07-04-2021-interim-statement-of-the-who-global-advisory-committee-on-vaccine-safety>
- WHO: COVIDX reaches over 100 economies, 42 days after first international delivery: <https://www.who.int/news/item/08-04-2021-covidx-reaches-over-100-economies-42-days-after-first-international-delivery>



IMPORTANT CONTACTS

- The National Focal Person is Dr. Najat Mohamed Abulfateh, email: NAI@health.gov.bh
- International Health Regulations focal person is Dr. Kubra Salman, email: knasser@health.gov.bh